The translational path is plausible only if development starts with pharmacodynamic window-finding, not with efficacy. TRPML1 has a strong mechanistic rationale because lysosomal dysfunction is shared across Alzheimer disease, Parkinson disease, ALS-FTD, and lysosomal storage disorders, and the paper-cache search surfaced a directly relevant report that the synthetic TRPML1 agonist ML-SA1 rescues Alzheimer-related endosomal-autophagic-lysosomal alterations. Reviews on lysosomal calcium in neurodegeneration and autophagy-lysosome dysfunction further support the target class. But clinical translation will fail unless the program distinguishes productive Ca2+ signalling from Ca2+ depletion.
The most actionable first indication is not broad sporadic Alzheimer disease. A better entry point is a genetically or biomarker-enriched lysosomal dysfunction cohort: LRRK2/Parkinson models, GBA-associated Parkinson disease, or AD patients with strong endolysosomal biomarker signatures. For tau or TDP-43 disease, TRPML1 agonism should be positioned as a proteostasis-restoration strategy only after showing that it improves neuronal survival and synaptic function, not merely aggregate burden.
A feasible preclinical package would use human iPSC-derived neurons and neuron-glia co-cultures, then an in vivo aged mouse or humanized disease model. Dosing should be explicitly adaptive: pulse duration, washout interval, and maximum exposure should be optimized against a biomarker panel. Minimum biomarkers should include lysosomal Ca2+ reserve, LysoTracker or pH readouts, cathepsin maturation, LC3 flux with bafilomycin controls, p62, TFEB nuclear localization, galectin-3 puncta, mitochondrial membrane potential, and inflammatory cytokines in glia.
Safety risk is substantial. Chronic lysosomal activation could alter lipid metabolism, iron handling, immune activation, and neuronal excitability. MCOLN1 loss causes severe lysosomal disease, but that does not mean gain-of-function is safe. The best clinical strategy is therefore a low-exposure pulsed agonist or indirect modulator, not a high-potency always-on channel opener. A go/no-go threshold should require a bell-shaped dose curve with a clear safety margin: at least a several-fold separation between the dose that improves flux and the dose that causes Ca2+ depletion or membrane permeabilization.